#Spain #Barcelona #pharmaceuticals #Rare Diseases #ESTEVE

ESTEVE Reports 5% Revenue Increase and Future Directions

BARCELONA, Spain – Esteemed pharmaceutical company ESTEVE has unveiled its 2024 annual financial performance, showcasing significant growth aligned with its strategic focus on enhancing the lives of individuals through specialized treatments. With a reported net revenue of €744 million, ESTEVE has achieved a commendable growth rate of 5% compared to the previous year, firmly positioning itself as a leading entity in the international pharmaceutical market.

The impressive revenue figures reveal that international sales constitute a substantial 75% of ESTEVE's overall income, demonstrating the effectiveness of its global strategy. Breaking down revenue sources, Spain accounts for 25%, while various European Union nations contribute a combined 53%, marking them as the fastest-growing regions. The remaining 22% of revenue is sourced from global markets beyond Europe.

At the forefront of this growth is the Pharma Business, which has realized over 15% growth in net revenues. Meanwhile, the CDMO (Contract Development and Manufacturing Organization) sector has maintained stable revenues, contributing positively with a focus on a higher value-added product mix. This remarkable performance is significantly attributed to the acquisition of HRA Pharma Rare Diseases in July 2024. This strategic acquisition introduces three critical treatments aimed at various serious conditions, reinforcing ESTEVE's commitment to addressing rare diseases and enhancing its presence in Europe and the United States.

The trend towards a highly specialized therapeutic focus is set to continue into 2025, as ESTEVE has finalized agreements to acquire another pivotal treatment recognized as the standard care for high-grade resectable non-metastatic osteosarcoma. Additionally, the company has secured in-licensing for a biological product targeting severe insulin-like growth factor 1 (IGF-1) deficiency in children and adolescents aged 2 to 18.

Staffan Schüberg, CEO of ESTEVE, expressed optimism regarding the company's trajectory, stating, "The results from last year not only reinforce our growth pattern established over the past four years but also reflect our unwavering dedication to enhancing life quality through specialized solutions. We are excited about what lies ahead as we strive to be a leading force in specialized medicine in the international pharmaceutical arena."

Innovation remains at the heart of ESTEVE’s strategy, as evidenced by a robust investment of €46 million directed toward product and process development, representing over 6% of the firm’s global net revenues. This commitment includes enhancements to manufacturing capabilities across its worldwide operations, with the recent launch of a new production site to replace its existing industrial facility in China and an expansion project for active pharmaceutical ingredient production in Celrà, Spain.

Moreover, ESTEVE’s social impact is noteworthy, with the company’s treatments reaching 8 million patients during 2024, targeting improvements in the quality of life for individuals affected by endocrinological disorders, oncology, and pain management. ESTEVE’s commitment to sustainability and inclusivity is also illustrated through its investment of more than €1.3 million in diversity initiatives, achieving a significant milestone with gender parity in management positions through a 50% representation of women in leadership roles.

In its pursuit of sustainability, ESTEVE is diligently working towards becoming a net-zero company by the year 2050. Notably, in 2024, the company sustained its operation on 100% renewable energy across all facilities, achieving a 5.8% reduction in carbon footprint compared to 2023 and a 10.41% reduction from 2022 levels. The organization also reports a 12% decrease in water consumption relative to the previous year, further demonstrating its commitment to environmental stewardship.

Founded in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical company committed to improving lives through highly specialized medical treatments. Its extensive international presence includes subsidiaries in Spain, Portugal, Italy, Germany, France, the UK, and the USA, making it a pivotal player in addressing significant unmet medical needs across various therapeutic areas. Besides its innovative pharmaceutical endeavors, ESTEVE also provides comprehensive Contract Manufacturing services, specializing in the production of Active Pharmaceutical Ingredients (APIs) through state-of-the-art facilities located in Spain, Mexico, and China.

In summary, ESTEVE’s performance in 2024 not only reflects its successful growth story but also its deep-seated values—people matter, transparency, and accountability—serving as fundamental pillars guiding its mission to enhance healthcare globally.